fashion -WSS

fashion

author：comprehensive 2025-10-01 15:39:32 - browse：4

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： AdventHealth escalates lawsuit against insurance vendor Multiplan

WSS

GSK Flovent asthma inhalers replaced by authorized generics

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

STAT Summit: The economic case for universal basic health care

Antibiotic resistance and the global rise in human conflict

AdventHealth escalates lawsuit against insurance vendor Multiplan

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Psychedelics group wrestles with new pharma identity

STAT Summit: Meghan O’Rourke on making chronic illness visible

Medical records are filled with copy

Antibiotic resistance and the global rise in human conflict

Activists slam private health insurers over coverage restrictions

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Anesthesiologist group: stop taking Ozempic before surgery

The biotech scorecard for Q1: 17 stock

Peter Hotez and the public health issue of online harassment

Roche acquires Telavant from Roivant, adding experimental IBD treatment

focus

Why a market frenzy over new weight loss drugs defies logic

The problems with dementia villages

J&J lung cancer data amount to new salvo against AstraZeneca

ADCs take center stage as promising cancer treatments

The biotech scorecard for Q1: 17 stock

Study on Amgen’s bispecific immunotherapy produces positive data

focus

leisure time

entertainment

knowledge